[Epidermal growth factor in the urine of patients with renal cell carcinoma and bladder tumor].
We evaluated the concentrations of immunoreactive epidermal growth factor (EGF) in urine samples from 14 patients with renal cell carcinoma, 16 patients with bladder tumor and 43 non-malignant controls by using radioimmunoassay. In the non-malignant controls, urinary EGF excretion significantly decreased with age (r = -0.46, p less than 0.01), and females excreted significantly more EGF than males [16.3 +/- 7.6 and 9.9 +/- 6.0 (mean +/- SD) ng/mg.creatinine; p less than 0.05]. There was no significant difference between urinary EGF excretion in the patients with renal cell carcinoma and non-malignant controls matched for sex and age (15.9 +/- 12.0 and 14.5 +/- 7.9 ng/mg.creatinine). The difference in excretion of EGF between the patients with bladder tumor and non-malignant controls also was not significant (9.9 +/- 5.6 and 11.7 +/- 7.0 ng/mg.creatinine). These findings indicate, that urine EGF has little usefulness as a tumor marker for renal cell carcinoma and bladder tumor.
Ishikura
K
K
Department of Urology, School of Medicine, Iwate Medical University.
Hasegawa
M
M
Nomura
K
K
Okamoto
T
T
Tanji
S
S
Abe
T
T
Fujioka
T
T
Ohhori
T
T
Kubo
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000652:urine*; D004815:Epidermal Growth Factor / Q000652:urine*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay / Q000379:methods; D001749:Urinary Bladder Neoplasms / Q000652:urine*
D004815:Epidermal Growth Factor